The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
复制标题
DOI：
10.1164/ajrccm.155.6.9196082
复制
发表时间：
1997-06-01
影响因子：
24.7
通讯作者：
Boushey, HA
中科院分区：
文献类型：
--
作者：
Fahy, JV;Fleming, HE;Boushey, HA
已显示针对人IgE的Fc区R1结合结构域的人源化鼠单克隆抗体（rhuMAb-E25）可抑制IgE与肥大细胞的结合，而不会引起肥大细胞活化。为了检测中和IgE对过敏性气道反应的影响，我们在一项平行组、随机、双盲、安慰剂对照研究中评估了19名过敏性哮喘受试者接受rhuMAb-E25治疗9周的效果。我们发现，rhuMAb-E25治疗降低了血清IgE，增加了激发早期哮喘反应所需的变应原剂量，减少了早期反应期间FEV 1的平均最大下降，（基线时30 +/- 10%至18.8 +/-8%，安慰剂治疗后基线时33 +/- 8%至34 +/- 4%; p = 0.01），并降低了迟发反应期间FEV 1的平均最大下降（基线时24 +/- 20%至9 +/- 10%对比基线时20 +/- 17%至安慰剂后18 +/-17%; p = 0.047）。我们的结论是，抗IgE单克隆抗体，抑制IgE结合其受体，抑制过敏性哮喘受试者吸入过敏原的早期和晚期反应。以IgE为靶点的rhuMAb-E25可能是治疗过敏性哮喘的有效方法。
A humanized murine monoclonal antibody directed to the FC epsilon R1-binding domain of human IgE (rhuMAb-E25) has been shown to inhibit the binding of IgE to mast cells without provoking mast cell activation. To examine the effects of neutralizing IgE on allergic airway responses, we assessed the effects of 9 wk of treatment with rhuMAb-E25 in a parallel group, randomized, double-blind, placebo-controlled study of 19 allergic asthmatic subjects. We found that treatment with rhuMAb-E25 reduced serum IgE, increased the dose of allergen needed to provoke an early asthmatic response, reduced the mean maximal fall in FEV1 during the early response (30 +/- 10% at baseline to 18.8 +/- 8%, versus 33 +/- 8% at baseline to 34 +/- 4% after placebo; p = 0.01), and reduced the mean maximal fall in FEV1 during the late response (24 +/- 20% at baseline to 9 +/- 10% versus 20 +/- 17% at baseline to 18 +/- 17% after placebo; p = 0.047). We conclude that an anti-IgE monoclonal antibody, which inhibits binding of IgE to its receptor, suppresses the early- and late-phase responses to inhaled allergen in allergic asthmatic subjects. Targeting IgE with rhuMAb-E25 might be a useful treatment for allergic asthma.